Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

por Vu, T, Gonsalves, W, Kumar, S, Dispenzieri, A, Lacy, M Q, Buadi, F, Gertz, M A, Rajkumar, S V
Publicado 2015

Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

por Chanan-Khan, A A, Swaika, A, Paulus, A, Kumar, S K, Mikhael, J R, Rajkumar, S V, Dispenzieri, A, Lacy, M Q
Publicado 2013

Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have co...

por Jacobus, S J, Rajkumar, S V, Weiss, M, Stewart, A K, Stadtmauer, E A, Callander, N S, Dreosti, L M, Lacy, M Q, Fonseca, R
Publicado 2016

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy

por Siontis, B, Kumar, S, Dispenzieri, A, Drake, M T, Lacy, M Q, Buadi, F, Dingli, D, Kapoor, P, Gonsalves, W, Gertz, M A, Rajkumar, S V
Publicado 2015

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era

por Chakraborty, R, Muchtar, E, Kumar, S K, Jevremovic, D, Buadi, F K, Dingli, D, Dispenzieri, A, Hayman, S R, Hogan, W J, Kapoor, P, Lacy, M Q, Leung, N, Gertz, M A
Publicado 2016

CD34(+) cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before...

por Holtan, S G, Hogan, W J, Elliott, M A, Ansell, S M, Inwards, D J, Porrata, L F, Johnston, P B, Micallef, I N, Lacy, M Q, Gastineau, D A, Litzow, M R
Publicado 2010

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

por Roy, V, Stewart, A K, Bergsagel, P L, Dispenzieri, A, Laumann, K, Allred, J, Lacy, M Q, Fonseca, R, Reeder, C B, Kumar, S, Rivera, C E, Gertz, M A, Buadi, F K, Hayman, S R, Rajkumar, S V
Publicado 2015

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

por Ravi, P, Kumar, S, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R S, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado 2017

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

por Gonsalves, W I, Leung, N, Rajkumar, S V, Dispenzieri, A, Lacy, M Q, Hayman, S R, Buadi, F K, Dingli, D, Kapoor, P, Go, R S, Lin, Y, Russell, S J, Lust, J A, Zeldenrust, S, Kyle, R A, Gertz, M A, Kumar, S K
Publicado 2015

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

por Ravi, P, Kumar, S, Larsen, J T, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado 2016

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

por Warsame, R, Kumar, S K, Gertz, M A, Lacy, M Q, Buadi, F K, Hayman, S R, Leung, N, Dingli, D, Lust, J A, Ketterling, R P, Lin, Y, Russell, S, Hwa, L, Kapoor, P, Go, R S, Zeldenrust, S R, Kyle, R A, Rajkumar, S V, Dispenzieri, A
Publicado 2015

Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience

por Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hayman, S., Kourelis, T., Warsame, R., Hwa, Y., Fonder, A., Hobbs, M., Muchtar, E., Leung, N., Kapoor, P., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Publicado 2023

Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma

por Binder, M, Rajkumar, S V, Ketterling, R P, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Publicado 2016

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

por Binder, M, Rajkumar, S V, Ketterling, R P, Greipp, P T, Dispenzieri, A, Lacy, M Q, Gertz, M A, Buadi, F K, Hayman, S R, Hwa, Y L, Zeldenrust, S R, Lust, J A, Russell, S J, Leung, N, Kapoor, P, Go, R S, Gonsalves, W I, Kyle, R A, Kumar, S K
Publicado 2017

Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design

por Vaxman, I., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Kapoor, P., Grogan, M., Go, R., Lin, Y., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A.
Publicado 2021

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib

por Kumar, S K, LaPlant, B, Roy, V, Reeder, C B, Lacy, M Q, Gertz, M A, Laumann, K, Thompson, M A, Witzig, T E, Buadi, F K, Rivera, C E, Mikhael, J R, Bergsagel, P L, Kapoor, P, Hwa, L, Fonseca, R, Stewart, A K, Chanan-Khan, A, Rajkumar, S V, Dispenzieri, A
Publicado 2015

“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience

por Vaxman, I., Abeykoon, J., Dispenzieri, A., Kumar, S. K., Buadi, F., Lacy, M. Q., Dingli, D., Hwa, Y., Fonder, A., Hobbs, M., Reeder, C., Sher, T., Hayman, S., Kourelis, T., Warsame, R., Muchtar, E., Leung, N., Go, R., Gonsalves, W., Siddiqui, M., Kyle, R. A., Rajkumar, S. V., Kristen, McCullough, Kapoor, P., Gertz, M. A.
Publicado 2021

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

por Tandon, N, Rajkumar, S V, LaPlant, B, Pettinger, A, Lacy, M Q, Dispenzieri, A, Buadi, F K, Gertz, M A, Hayman, S R, Leung, N, Go, R S, Dingli, D, Kapoor, P, Lin, Y, Hwa, Y L, Fonder, A L, Hobbs, M A, Zeldenrust, S R, Lust, J A, Gonsalves, W I, Russell, S J, Kumar, S K
Publicado 2017